Agenus Inc., a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system for patients suffering with cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies. It is also developing checkpoint modulating antibody candidates targeting GITR, OX40, TIM-3, and LAG-3. In addition, the company develops vaccine programs, such as Prophage cancer vaccine candidate; AutoSynVax, a synthetic cancer vaccine program targeting the neo-epitope landscape in cancer patients; and PhosPhoSynVax, a vaccine candidate designed to induce immunity against a novel class of tumor specific neo-epitopes. Further, Agenus Inc. develops QS-21 Stimulon, a saponin-based vaccine adjuvant that has completed Phase III clinical trials for the treatment of malaria and shingles. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
http://www.priceseries.com/trade/AGEN-Agenus-Inc-stock-gains-43-percent-a-Trade-Record-by-priceSeries-2018021420180315.html
Subscribe by Email
Follow Updates Articles from This Blog via Email
No Comments